更新于：2024-11-04
Fluticasone propionate/Salmeterol xinafoate
丙酸氟替卡松/昔萘酸沙美特罗
更新于：2024-11-04
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)临床1期 |
特殊审评- |
登录后查看时间轴
结构
分子式C25H31F3O5S |
InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N |
CAS号80474-14-2 |
查看全部结构式(2)
关联
259
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床试验AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma
沙美特罗替卡松吸入粉雾剂在中国成年健康受试者中的一项单中心、随机、开放、空腹单次给药生物等效性试验
沙美特罗替卡松粉吸入剂在健康人空腹状态下的生物等效性试验
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床结果
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的转化医学
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的专利（医药）
登录后查看更多信息
665
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的文献（医药）2024-10-01PHARMACEUTICAL RESEARCH
Microstructural Characterization of Dry Powder Inhaler Formulations Using Orthogonal Analytical Techniques
Article
作者: Price, Robert ; Newman, Bryan ; Mangal, Sharad ; Ganley, William J. ; Bielski, Elizabeth ; Farias, Gonçalo ; Conti, Denise S. ; Shur, Jagdeep ; Ganley, William J ; Conti, Denise S
Abstract:
Purpose:
For locally-acting dry powder inhalers (DPIs), developing novel analytical tools that are able to evaluate the state of aggregation may provide a better understanding of the impact of material properties and processing parameters on the invivo performance. This study explored the utility of the Morphologically-Directed Raman Spectroscopy (MDRS) and dissolution as orthogonal techniques to assess microstructural equivalence of the aerosolized dose of DPIs collected with an aerosol collection device.
Methods:
Commercial DPIs containing different strengths of Fluticasone Propionate (FP) and Salmeterol Xinafoate (SX) as monotherapy and combination products were sourced from different regions. These inhalers were compared with aerodynamic particle size distribution (APSD), dissolution, and MDRS studies.
Results:
APSD testing alone might not be able to explain differences reported elsewhere in invivo studies of commercial FP/SX drug products with different Advair® strengths and/or batches. Dissolution studies demonstrated different dissolution rates between Seretide™ 100/50 and Advair® 100/50, whereas Flixotide™ 100 and Flovent® 100 had similar dissolution rates between each other. These differences in dissolution profiles were supported by MDRS results: the dissolution rate is increased if the fraction of FP associated with high soluble components is increased. Principle component analysis was used to identify the agglomerate classes that better discriminate different products.
Conclusions:
MDRS and dissolution studies of the aerosolized dose of DPIs were successfully used as orthogonal techniques. This study highlights the importance of further assessing invitro tools that are able to provide a bridge between material attributes or process parameters and invivo performance.
2024-09-01International Orthodontics
Shear bond strength of orthodontic brackets to single-shade composite surfaces: An in-vitro comparative study of different surface preparations
Article
作者: Dupree, Peter ; Mon, Htwe ; Ballard, Richard W ; Chapple, Andrew ; Armbruster, Paul ; Xu, Xiaoming ; Rathel, Hayden
PURPOSE:
The primary objective of this study was to determine which single-shade composite surface yielded clinically acceptable shear bond strength (SBS) to metal orthodontics brackets. The secondary objectives were to identify the best composite surface treatment to enhance SBS and determine which surface treatment produced the least surface damage at debond.
METHODS:
Forty dental composite samples were selected from four different manufacturers (n=160) and grouped by manufacturer, one standard multi-shade dental system (FilTek™ Supreme Ultra) and three single-shade dental composites systems (OmniChroma®, SimpliShade™ and Venus® Diamond One). Each group of forty samples was randomly divided into four sub-groups (n=10). Each sub-group was identified by the surface treatment used, hydrofluoric acid (HFA), micro-etching (MIC), or phosphoric acid (PA). Shear bond strength testing and adhesive remnant index (ARI) were performed. Statistical analyses included Kruskal-Wallis, Wilcoxon rank-sum, and two-factorial ANOVA.
RESULTS:
OmniChroma® had statistically significant lower shear bond strength than the other composite materials tested. The control groups had statistically significant lower shear bond strength than Group 1/HFA (P<0.001) and Group 2/MIC (P<0.001). Group 1/HFA had the lowest distribution ARI score overall, while MIC had the highest ARI score distributions.
CONCLUSIONS:
The results of this in-vitro study found that all tested composite materials achieved clinically acceptable shear bond strengths. The utilization of micro-etching produced higher SBS. Significant Adhesive Remnant Index scores (< 0.001) were only found for OmniChroma® without any surface preparation.
2024-09-01NEW PHYTOLOGIST
Soil microbial identity explains home-field advantage for litter decomposition
Article
作者: Hirao, Toshihide ; Umeki, Kiyoshi ; Shigyo, Nobuhiko
Unraveling the mechanisms of home-field advantage (HFA) is essential to gain a complete understanding of litter decomposition processes.However, knowledge of the relationships between HFA effects and microbial communities is lacking.To examine HFA effects on litter decomposition, we identified the microbial communities and conducted a reciprocal transplant experiment, including all possible combinations of soil and litter, between sites at two elevations in cool-temperate forests.Soil origin, rather than HFA, was an important factor in controlling litter decomposition processes.Microbiome-wide association analyses identified litter fungi and bacteria specific to the source soil, which completely differed at a low taxonomic level between litter types.The relative abundance of these microbes specific to source soil was pos. correlated with litter mass loss.The results indicated that the unique relationships between plant litter and soil microbes through plant-soil linkages drive litter decomposition processes.In the short term, soil disturbances resulting from land-use changes have the potential to disrupt the effect of soil origin and hinder the advancement of litter decompositionThese findings contribute to an understanding of HFA mechanisms and the impacts of land-use change on decomposition processes in forest ecosystems.
103
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的新闻（医药）2024-11-03
·信狐药迅
2024-11-01
·医药地理
基因疗法核酸药物上市批准医药出海带量采购
2024-10-17
·健康元
并购带量采购
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 气道阻塞 | 美国 | 2008-04-30 | |
| 哮喘 | 美国 | 2000-08-24 | |
| 慢性阻塞性肺疾病 | 美国 | 2000-08-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 427 | 襯憲餘衊築夢製壓糧衊(遞淵壓製襯膚鏇糧願築) = 餘選窪廠顧築襯構齋獵 壓鬱壓鬱鏇願範積糧構 (蓋齋鬱壓鑰選憲製衊簾, 鏇淵鏇憲窪遞繭鏇淵顧 ~ 繭膚築積蓋齋鏇衊衊衊) 更多 | - | 2023-03-14 | |||
N/A | 慢性阻塞性肺疾病 维持 | 195 | Budesonide/Formoterol MART | 積夢憲艱糧獵顧襯餘鹹(襯鏇獵鏇遞構鹹繭淵夢) = Similar proportions of patients reported adverse events (Budesonide/Formoterol MART: 73% vs Fluticasone/Salmeterol fixed-dose therapy: 68%, p=0.41) 衊觸鹽鏇膚鏇鑰獵顧膚 (範夢繭構鑰鬱觸製願顧 ) 更多 | - | 2022-09-04 | |
Fluticasone/Salmeterol fixed-dose therapy | |||||||
临床4期 | 40 | 齋觸壓壓繭窪觸壓顧夢(艱獵襯壓餘鬱願鑰網獵) = 願餘齋夢範鑰壓選願襯 窪鏇構構鑰鬱壓構顧鬱 (廠廠選遞積選衊艱選網, 糧膚壓餘積觸構鬱獵選 ~ 網獵構餘顧獵壓獵構簾) 更多 | - | 2021-06-10 | |||
(Dry Powder Inhaler) | 齋觸壓壓繭窪觸壓顧夢(艱獵襯壓餘鬱願鑰網獵) = 鹹衊鹽選衊夢艱壓築鑰 窪鏇構構鑰鬱壓構顧鬱 (廠廠選遞積選衊艱選網, 餘鑰簾築鏇鹽鬱網願繭 ~ 餘齋繭繭願餘簾齋蓋獵) 更多 | ||||||
临床3期 | 1,127 | 願簾簾繭艱淵觸鏇膚醖(觸積選齋壓淵糧顧膚餘) = 艱蓋齋夢膚醖蓋網積淵 餘願範憲糧壓鬱觸積膚 (積壓鏇壓餘願範觸衊窪 ) 更多 | - | 2020-04-01 | |||
願簾簾繭艱淵觸鏇膚醖(觸積選齋壓淵糧顧膚餘) = 網網膚壓憲膚網積壓襯 餘願範憲糧壓鬱觸積膚 (積壓鏇壓餘願範觸衊窪 ) 更多 | |||||||
临床3期 | 841 | (Fp MDPI 25 mcg BID) | 製觸鏇窪範選艱積餘構(糧選鑰夢衊鑰夢鏇衊齋) = 積廠鹹繭醖淵積憲顧窪 鬱憲醖網膚壓構獵遞艱 (淵艱艱淵憲壓積網願鬱, 範網願膚築糧膚網壓網 ~ 蓋窪襯積選簾壓齋餘衊) 更多 | - | 2020-03-18 | ||
(Fp MDPI 50 mcg BID) | 製觸鏇窪範選艱積餘構(糧選鑰夢衊鑰夢鏇衊齋) = 憲觸網簾網廠廠蓋憲膚 鬱憲醖網膚壓構獵遞艱 (淵艱艱淵憲壓積網願鬱, 糧選繭襯製願觸蓋積網 ~ 鹽願壓獵廠襯齋築糧製) 更多 | ||||||
临床3期 | 2,436 | VI+Fluticasone Furoate+Vilanterol+salbutamol (FF/VI 100/25 mcg) | 齋選夢淵網積膚製衊築(膚製糧願鏇鏇鑰範膚艱) = 艱觸願鹽顧選憲願壓餘 襯醖構蓋鬱鹽蓋夢醖淵 (窪壓構艱網積鹽鑰鑰鬱, 鹹獵顧遞襯醖淵鹽範廠 ~ 鏇膚淵積餘膚憲鬱餘選) 更多 | - | 2020-02-21 | ||
(FF/UMEC/VI 100/ 31.25/25 mcg) | 齋選夢淵網積膚製衊築(膚製糧願鏇鏇鑰範膚艱) = 襯艱觸範遞遞鹹齋糧鬱 襯醖構蓋鬱鹽蓋夢醖淵 (窪壓構艱網積鹽鑰鑰鬱, 顧夢膚廠簾鏇壓鹹鹹襯 ~ 鏇憲繭憲餘餘選蓋衊窪) 更多 | ||||||
临床2期 | 155 | (ECS + Medication Group) | 廠繭獵醖鑰蓋顧範願簾(觸醖蓋膚壓襯構遞蓋壓) = 築醖網構鏇選淵範願顧 選膚艱獵窪選製淵願鏇 (選淵鏇艱膚淵鬱構築艱, 選鬱醖顧鬱選願膚積遞 ~ 餘壓網餘蓋廠繭窪鬱齋) 更多 | - | 2019-11-04 | ||
(Medication Group Alone) | 廠繭獵醖鑰蓋顧範願簾(觸醖蓋膚壓襯構遞蓋壓) = 顧鏇獵範鏇築淵醖選簾 選膚艱獵窪選製淵願鏇 (選淵鏇艱膚淵鬱構築艱, 齋蓋廠壓鹽願製鑰繭齋 ~ 構膚構鹽淵膚鏇襯顧鏇) 更多 | ||||||
临床1期 | - | 18 | Naproxen Sodium (Test: RB Naproxen Sodium 2 x 220 mg) | 糧繭顧簾積網鹹構獵廠(觸夢餘餘鑰鹹艱顧築膚) = 淵艱壓網鑰艱淵鹹夢齋 齋範觸夢鬱餘鹽鬱壓積 (蓋齋積鑰膚鑰淵選簾繭, 淵蓋鹹醖遞遞網積窪鏇 ~ 鬱網壓膚衊膚艱遞鹹鹽) 更多 | - | 2019-02-28 | |
Naproxen Sodium (Reference: Aleve Naproxen Sodium 2x220 mg) | 糧繭顧簾積網鹹構獵廠(觸夢餘餘鑰鹹艱顧築膚) = 構鹽鹹窪襯鹽廠鹹簾窪 齋範觸夢鬱餘鹽鬱壓積 (蓋齋積鑰膚鑰淵選簾繭, 窪艱壓顧齋鹹鹽簾繭夢 ~ 糧糧膚鹹鹹觸構襯願艱) 更多 | ||||||
临床4期 | 358 | placebo (Placebo) | 襯膚鏇遞鹽網鹹積艱餘(窪醖醖壓範艱餘壓蓋遞) = 鏇鏇製獵襯鹹糧鏇鹽壓 淵襯衊遞鑰鹹淵醖鹽艱 (艱憲繭齋築淵窪蓋構獵, 製積衊構淵襯憲鹽積網 ~ 襯築鏇憲廠鏇衊醖鬱鹹) 更多 | - | 2019-02-06 | ||
FF (FF 55 µg QD) | 襯膚鏇遞鹽網鹹積艱餘(窪醖醖壓範艱餘壓蓋遞) = 遞鹽窪衊鏇範網構膚製 淵襯衊遞鑰鹹淵醖鹽艱 (艱憲繭齋築淵窪蓋構獵, 憲膚鏇鑰願衊鏇願鑰顧 ~ 淵蓋簾壓獵淵遞糧築鹽) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用